Atossa Therapeutics and Quantum Leap Healthcare Announce New Study Arm to Evaluate (Z)-Endoxifen in the Ongoing I-SPY 2 Clinical Trial https://t.co/5VMsykbEnI
Atossa Doses First Patient in Phase 2 Neoadjuvant Clinical Study of (Z)-Endoxifen in Premenopausal Women with ER+/HER2- Breast Cancer https://t.co/UX0ki5Ks3I
Atossa Therapeutics, Inc. Receives Authorization from FDA to Initiate its Phase 2 Study of Neoadjuvant (Z)-endoxifen in Premenopausal Women with ER+/HER2- Breast Cancer https://t.co/UD4j5LMiOs
Registration Now Open for Tribe Public’s Webinar Event “The Important Role For Inhalation Therapy In Oncology” Featuring The Management Team From Atossa Therapeutics on August 25, 2022 https://t.co/xicMhZeokY
Atossa Therapeutics, Inc. Receives Authorization from FDA to Initiate its Phase 2 Study of Neoadjuvant (Z)-endoxifen in Premenopausal Women with ER+/HER2- Breast Cancer https://t.co/uT0YQ0LE1U
Registration Now Open for Tribe Public’s Webinar Event “The Important Role For Inhalation Therapy In Oncology” Featuring The Management Team From Atossa Therapeutics on August 25, 2022 https://t.co/QxCjLulnzw